Chai Discovery Raises $400 Million in Series C Round
Chai Discovery, a San Francisco-based company specializing in artificial intelligence to predict and reprogram biochemical molecular interactions, has announced the successful closure of a $400 million Series C funding round. The round, dated July 14, 2026, was led by prominent investors including Index Ventures, Kleiner Perkins, Sequoia Capital, and Dimension.
Investment Details
The Series C round saw participation from a diverse group of investors, alongside the lead investors. These included Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT and MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite. The considerable investment highlights the strong interest and confidence in Chai Discovery's innovative approach to biochemical research.
Company Vision and Leadership
Chai Discovery is at the forefront of developing cutting-edge AI technologies aimed at understanding and manipulating the interactions between biochemical molecules. The company was co-founded by a team of experts including Jack Dent, Jacques Boitreaud, Joshua Meier, and Matthew McPartlon. Their collective expertise drives the company's mission to revolutionize the field of biochemical research through advanced AI solutions.
Strategic Use of Funds
While specific allocations were not disclosed, it is anticipated that the newly secured funds will be directed towards expanding Chai Discovery's research capabilities, enhancing their AI technology, and possibly increasing their workforce to support these expansions. The infusion of capital is expected to accelerate the company's efforts in pioneering new applications for their AI technology in biochemical research.
Conclusion
The substantial Series C funding marks a significant milestone for Chai Discovery as it continues to innovate at the intersection of artificial intelligence and biochemistry. With strong backing from a range of leading investors, the company is well-positioned to advance its technological capabilities and further its impact on the scientific community.